This narrative review describes the current landscape as well future directions for use of immune checkpoint inhibitors in recurrent or metastatic head and neck carcinoma. ja.ma/41KuVXc Glenn J. Hanna, M.D.

Thank you Daniel Ma for the invitation to join the Mayo Clinic Comprehensive Cancer Center #headandneck #cancer symposium. Fantastic sessions. Great to share the stage with the always entertaining Glenn J. Hanna, M.D.!

We had a fantastic time at #ESMORareCancers25 presenting our #salivaryglandcancer #research working group & a poster, in addition to catching up with colleagues from all over Europe & the US 👋👋EURACAN ESMO - Eur. Oncology #UKSGCRWG

Actuate announced that promising data on elraglusib in advanced salivary gland carcinoma will be presented in a poster session at the AACR Annual Meeting 2025 on Tuesday, April 29th. For poster presentation details: bit.ly/4imxzYj $ACTU #AACR25

Dr. Glenn Hanna (Glenn J. Hanna, M.D.), Director of the CCTI, the early drug development program at Dana-Farber, comments on the promising data on elraglusib in advanced salivary gland carcinoma to be presented in a poster session at #AACR25. Read more: bit.ly/4imxzYj $ACTU

A huge thanks to Glenn Hanna, MD, of Dana-Farber, who sat down with us during #AACR25 to discuss the use of elraglusib plus chemo and immunotherapy in salivary gland cancer! See our site for more from the meeting. Glenn J. Hanna, M.D. AACR #hncsm #oncology onclive.com/conference/aacr

Amazing results. Will change standard of care. Congratulations to Ravi Uppaluri (Ravi Uppaluri, MDPhD⁩), Doug Adkins, and team! ⁦WashUMedENT⁩ ⁦WashU Medicine⁩ ⁦AHNS⁩

Reminder: Actuate will present data on its lead investigational drug, elraglusib, in advanced salivary gland carcinoma during a poster session at the AACR Annual Meeting 2025, tomorrow, April 29th at 2 PM CT. For more details, visit: bit.ly/4imxzYj $ACTU #AACR25

Charles Kung presenting REM-422, a first-in-class, orally available small molecule degrader of MYB mRNA at #AACR today. REM-422 induces tumor regressions in MYB-dysregulated preclinical models at well tolerated doses & is in two Phase 1 clinical trials. bit.ly/4c4FkAr

Encouraging new data at #AACR25 on micvotabart pelidotin (next-generation ADC that targets EDB+FN). Extracellular cleavage ADCs seem to have potential. Focusing on EDB+FN overexpressed in the TME may elicit sustained anti-tumor response. Pyxis Oncology

At AACR Glenn J. Hanna, M.D. of Dana-Farber says phase II findings are relatively encouraging for pts with advanced salivary tumors, a population with high unmet clinical need with no current approved therapies. The study looked at elraglusib + chemotherapy.

‼️Our paper on clinical trials for patients with salivary gland cancers is now published! 🙌80% funded by Academia. Need to attract pharma interest! 🟠50% unicenter, 80% single country. Need for ⬆️ collaboration! 🟠55% enrolled any type of histologies without stratification

🎙️ Throwback Thursday: Immunobuddies Podcast Highlight from November 2023! 🎇 🧡 Managing Immunotherapy in Organ Transplant Patients 🧡 📍 Featuring: Dr. Glenn Hanna Associate Professor, Harvard Medical School Dana-Farber Cancer Institute, Boston 🩺 A 2-part deep dive into: ✅

Early morning press briefing at #asco25 ASCO

Dr. Glenn J. Hanna, M.D. explains how adding nivolumab to chemoradiotherapy after surgery can decrease chance of recurrence in patients with head and neck cancers. Learn more: brnw.ch/21wT4NC #ASCO25 #hncsm

💊 Breaking science, straight from #ASCO25: #Nivolumab ➕standard chemoradiotherapy slashed risk for recurrence or death by 2⃣4⃣% in patients with resected, locally advanced #HNSCC 💡 “Tremendous” results, noted Dr. Glenn J. Hanna Glenn J. Hanna, M.D. Dana-Farber healio.com/news/hematolog…

Today at #ASCO25: Glenn J. Hanna, M.D. of Dana-Farber presents phase 2 data suggesting circulating HPV DNA can be a biomarker before & during treatment for HPV-positive oropharyngeal cancer to guide treatment intensity w/o compromising PFS survival in higher-risk pts.

⏰🚨👏ReACT1.0 #ASCO25 Glenn J. Hanna, M.D. Jonathan Schoenfeld Dr. Danielle Margalit Robert Haddad 🌟 Ph2, stage I-III HPV+ OPC 🌟54-66Gy gross dz based on risk/DNA clearance 🌟30-54Gy elective 🌟~60%>95% clearance at wk 4-5 🌟2yr PFS 90% - 5 events (1 death): 3LRR, 4DM

Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by U.S. News & World Report, ranked as #3 in the nation and the only one top ranked in New England for 2025-26. Learn more: bit.ly/45e0n0x